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Abstract
Background: Optimizing patient selection is a necessary step to design better clinical trials. ‘Life expectancy’ is a
frequent inclusion criterion in phase II trial protocols, a measure that is subjective and often difficult to estimate.
The aim of this study was to identify factors associated with early death in patients included in phase II studies.
Methods: We retrospectively collected medical records of patients with advanced solid tumors included in phase II
trials in two French Comprehensive Cancer Centers (Bordeaux, Center 1 set; Lille, Center 2 set). We analyzed
patients’ baseline characteristics. Predictive factors associated with early death (mortality at 3 months) were
identified by logistic regression. We built a model (PREDIT, PRognostic factor of Early Death In phase II Trials) based
on prognostic factors isolated from the final multivariate model.
Results: Center 1 and 2 sets included 303 and 227 patients, respectively. Patients from Center 1 and 2 sets differed
in tumor site, urological (26 % vs 15 %) and gastrointestinal (18 % vs 28 %) and in lung metastasis incidence (10 %
vs 49 %). Overall survival (OS) at 3 months was 88 % (95 % CI [83.5; 91.0], Center 1 set) and 91 % (95 % CI [86.7; 94.
2], Center 2 set). Presence of a ‘life expectancy’ inclusion criterion did not improve the 3-month OS (HR 0.6, 95 % CI
[0.2; 1.2], p = 0.2325). Independent factors of early death were an ECOG score of 2 (OR 13.3, 95%CI [4.1; 43.4]),
hyperleukocytosis (OR 5.5, 95 % CI [1.9; 16.3]) and anemia (OR 2.8, 95 % CI [1.1; 7.1]). Same predictive factors but
with different association levels were found in the Center 2 set. Using the Center 1 set, ROC analysis shows a good
discrimination to predict early death (AUC: 0.89 at 3 months and 0.86 at 6 months).
Conclusions: Risk modeling in two independent cancer populations based on simple clinical parameters showed
that baseline ECOG of 2, hyperleukocytosis and anemia are strong early-death predictive factors. This model allows
identifying patients who may not benefit from a phase II trial investigational drug and may, therefore, represent a
helpful tool to select patients for phase II trial entry.
Keywords: Phase II trial, Early death, Prognostic factors, “life expectancy” criterion, Drug trials
* Correspondence: A.Italiano@bordeaux.unicancer.fr
1Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer
Centre Bordeaux, 229 cours de l’Argonne, 33076 Bordeaux, France
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Grellety et al. BMC Cancer  (2016) 16:768 
DOI 10.1186/s12885-016-2819-7
Background
Phase II trials in oncology are an essential part in anti-
cancer drug development as they provide relevant data
regarding toxicity and proof of efficacy. These assess-
ments are necessary to make the ‘go or no-go’ decision
before starting large controlled randomized phase III
trials [1]. In oncology, there are more phase II (45 % vs
23 %) but fewer phase III (13 % vs 23 %) trials than in
other specialties [2]. Phase II to phase III represents the
riskiest transition point of the drug development
pathway [3, 4], as proven by the very high attrition rate
between a successful phase II and the subsequent phase
III trial. Enhancing the overall quality of phase II trials is
therefore critical for drug development, and could bene-
fit from changes at several levels, from the use of
randomization in the study design [5] to the improve-
ment in the quality of publication [6]. Furthermore,
there is a need to rethink the selection of large numbers
of patients for phase II trials that raise ethical and cost
questions. Indeed, patient selection has been recognized
as being of upmost importance in the design of clinical
trials [7]. Although many efforts have been made in
phase I trials wherein a careful patient selection likely
increases the benefit of the trial to patients, no such ini-
tiative has been taken for phase II trials. Similarly, there
is an increase in the average number of inclusion criteria
for phase II trials, such as ‘sufficient life expectancy’ at
screening [8]. Life expectancy is difficult to estimate in
clinical practice and depends on the physician’s consid-
eration, making it not only irreproducible but also insuf-
ficient to predict any benefit for the patient, as most
patients enroll with a hope for therapeutic benefit [9].
Ethical consideration should therefore lead physicians to
include patients only in cases of potential benefit from
the investigational drug. This would require identifying
those patients that would survive long enough for the
investigational treatment to be effective. Despite the cru-
cial role of phase II trials in drug development, no tool
has been published that allows a better selection of pa-
tients based on their prognostic. The aim of this pilot
study is to develop a model to identify prognostic factors
of early death in adult cancer patients included in oncol-
ogy phase II trials based on two sets of patients from
two French Comprehensive Cancer Centers. Relevant
prognostic factors will help investigators identify partici-
pants unsuitable for such studies.
Methods
Selection of patients
The first patient set (Center 1 set) included all patients in-
volved in phase II clinical trials at the Institut Bergonié,
Comprehensive Cancer Center (Bordeaux, France),
between January 2008 and December 2012. We selected
all trials investigating anticancer drugs and having
included adults (aged 18 or older) with advanced or meta-
static solid tumors. Trials investigating supportive care,
surgical procedures or radiotherapy were excluded. Pa-
tients had received at least one dose of the investigational
agent. The second set (Centre 2 set) was from the Oscar
Lambret Cancer Center (Lille, France), with all patients in-
cluded in a phase II clinical trial between January 2011
and July 2014 that met the same criteria.
For each patient, retrospective baseline data were re-
corded at inclusion in the phase II trial: age, gender,
body mass index (BMI), ECOG performance status, hist-
ology, number and sites of metastasis, treatment type,
biological data (serum albumin, Lactate Dehydrogenase
(LDH), platelets, leukocyte and lymphocyte counts,
hemoglobin level, sodium, potassium and calcium level,
alkaline phosphatase, alanine and aspartate transaminase
and c-reactive protein). Furthermore, for each patient we
recorded the date of inclusion, and date and cause of
study withdrawal.
The following data regarding the design of the clinical
trials were extracted from each protocol: presence of a
“life expectancy” inclusion criterion, randomized trial (Yes
vs No), number of previous treatment lines authorized
and nature of the promoter (academic vs industrial). Study
data were collected and managed using REDCap
electronic data capture tools [10].
Statistical methods
Variables were described using median, mean and ex-
treme values. Categorical variables were classified based
on the normal values (for biological variables, BMI). Bio-
logical variables were classified as normal, below normal
and above normal. Overall survival (OS) was defined as
the time from inclusion in a trial to death from any
cause. Patients lost during follow-up were censored at
their last visit. Survival was estimated using the Kaplan–
Meier method. For our main analysis, we used early
deaths, defined as all deaths occurring up to 3 months
from inclusion. We also performed a secondary analysis
for deaths occurring up to 6 months from inclusion.
Three- and six-month’ cut-off ’s were chosen due to their
discriminant nature in the detection of prognostic factors.
Three months represents the classical cut-off point for the
first evaluation of safety and efficacy in clinical trials. It
has commonly been used in studies of prognostic factors
for patients included in phase I trials [11, 12] and is rele-
vant regarding the median overall survival of 9.4 months
for patients included in phase II trials, as published in a
recent meta-analysis by Schwaederle M. et al. [13].
On the Center 1 set, we performed a logistic model to
estimate odds ratio (OR) and 95 % confidence interval
(95 % CI) of the association between early death and clin-
ical or biological variables. All variables associated with a
significantly increased risk of early death (p < 0.05) were
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considered for multivariate analysis. Variables such as age,
sex and tumor localization were included in all models
due to clinical relevance. Selection of variables for the
multivariate model was performed following a step-by-
step forward strategy. In order to limit the number of vari-
ables in the final multivariate model, clinical and labora-
tory variables were first selected in two separate specific
multivariate models using stepwise logistic approach. Each
clinical and biological variable selected in their respective
multivariate model was entered into a third and final
model before adjusting for age, sex and tumor localization.
The threshold of 0.05 for statistical significance was used
to maintain the variable in the model. The stringent alpha
level allowed limiting the selection to those factors that
are relevant from a clinician’s perspective.
A model (PREDIT, PRognostic factor of Early Death In
phase II Trial) was built with the prognostic factors iso-
lated from the final multivariate model in the Center 1
set. Adequacy was established using the Hosmer &
Lemeshow test. [14]. Discrimination of mortality at 3
and 6 months was evaluated using the receiver operator
characteristic area under the curve (AUC). Finally, we
performed the same analyses in the Centre 2 set. Statis-
tical analyses were carried out using the SAS software,
version 9.3 (SAS Institute, Inc., Cary, NC).
Results
Characteristics of the trials
Fifty-one trials were included for analysis in the Center
1 set and 40 in the Center 2 set, with recruitment ran-
ging from one to 31 patients. Patient characteristics are
described in Table 1. Twenty-six trials (51 %) in the
Center 1 set and 27 trials in the Center 2 set (68 %) were
sponsored by a pharmaceutical company. Most phase II
trials were randomized (59 % in the Center 1 set and
63 % in the Center 2 set). Treatments differed between
Table 1 Characteristics of trials and outcomes for Center 1 and Center 2 sets
Characteristics Center 1 Set (N = 303) Center 2 Set (N = 227) P Chi2
N (%) Median (Min-Max) N (%) Median (Min-Max)
Number of trials 51 40
Patients by trials 4 (1–31) 2 (1–22)
Trial randomization 0.13
Yes 30 (59) 25 (63)
No 21 (41) 15 (37)
Trial promotion 0.08
Academic 25 (49) 27 (68)
Industrial 26 (51) 13 (32)
Protocol defined treatments <0.001
Chemotherapy-based regimen 154 (51) 157 (69)
Targeted therapies only (targeted therapies and/or endocrine therapy) 149 (49) 70 (31)
Protocol specified “life expectancy” criterion (per patient) 0.003
Yes 73 (24) 82 (36)
No 230 (76) 145 (64)
Treatment duration (months) 4 (0–44) 4 (0–49)
Reason for discontinuing trial <0.001
Progression 198 (65) 136 (60)
Programmed end of the trial 42 (14) 6 (3)
Toxicity 32 (10) 37 (16)
Death 12 (4) 2 (1)
Patient Retrial 8 (3) 9 (4)
Other 8 (3) 18 (8)
NA 3 (1) 19 (8)
Median follow-up (months) 17 (0–77) 12 (0–50)
Three-month mortality rate 37 (12) 20 (9)
Six-month mortality rate 59 (20) 41 (18)
Abreviations: NA not available
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Table 2 Clinical and biological characteristics at baseline for Center 1 and Center 2 sets
Characteristics at baseline Center 1 Set (N = 303) Center 2 Set (N = 227) P Chi2
N (%) Median (Min-Max) N (%) Median (Min-Max)
Sex 0.64
Male 181 (60) 131 (58)
Female 122 (40) 96 (42)
Age 62 (IQR, 19) 60 (IQR, 23) 0.07
< 50 55 (18) 42 (19)
50–65 116 (38) 107 (47)
≥ 65 132 (44) 78 (34)
Performance status 0.82
ECOG 0–1 278 (92) 207 (91)
ECOG 2 25 (8) 20 (9)
BMI (kg/m2) 25 (16–39) 26 (16–45) -a
< 18.5 13 (4) 9 (4)
18.5–25 147 (49) 83 (37)
≥ 25 143 (47) 107 (47)
NA 0 28 (12)
Previous treatments 1 (0–4) 1 (0–6) <0.001
0 9 (3) 106 (47)
1 185 (61) 67 (30)
2 74 (24) 32 (14)
3 27 (9) 19 (8)
4 and more 8 (3) 3 (1)
Cancer localization 0.01
Sarcomas 123 (40) 91 (40)
Urological 78 (26) 35 (15)
Gastrointestinal 54 (18) 63 (28)
Breast 29 (10) 20 (9)
Other 19 (6) 18 (8)
Involved areas 0.55
Loco-regional disease 18 (6) 19 (8)
1–2 metastatic sites 223 (74) 164 (72)
≥ 3 metastatic sites 62 (20) 44 (19)
Hemoglobin level 0.08
< Normal 106 (35) 94 (41)
Normal 196 (65) 126 (56)
NA 1 (0.3) 7 (3)
Leukocyte level 0.18
< Normal 14 (5) 15 (6)
Normal 255 (84) 171 (75)
> Normal 33 (11) 33 (15)
NA 1 (0.3) 8 (4)
Albumin level -a
< Normal 25 (8) 87 (38)
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the two sets: whereas the ratio between targeted therapy
(149, 49 %) and chemotherapy (154, 51 %) was well-
balanced in the Center 1 set, chemotherapy was more
frequently used (157, 69 %) in the Center 2 set.
Patient characteristics
The Center 1 and Center 2 sets included 303 and 227
patients, respectively. Median age was 62 years (Inter-
quartile Range, 19) in the Center 1 set and 60 (Inter-
quartile Range, 23) years in the Center 2 set. The male
to female ratio was similar in both sets (Center 1 set: 1.5
and Center 2 set: 1.4). Primary tumor sites were equally
distributed for sarcomas (123, 41 %; 91, 40 %) and breast
(29, 10 %; 20, 9 %) but differed significantly for uro-
logical (78, 26 %; 35, 15 %) and gastrointestinal (54,
19 %; 63, 28 %) cancers. There were 241 (80 %) and 183
(81 %) patients with two or less metastatic sites in the
Center 1 and Center 2 sets, respectively. Occurrence of
liver metastases was similar in both groups, (Center 1
set: 106, 35 %; Center 2 set: 73, 32 %) whereas lung
metastases were rarer in the Center 1 set (Center 1 set:
30, 10 %; Center 2 set: 111, 49 %); there was more bone
and extra-regional lymph nodes involvement in the
Center 1 set. Median number of previous lines of treat-
ment was one (Center 1 set: range 0–4; Center set: range
0–6). Clinical and biological values at baseline are de-
scribed in Table 2.
General description
Median time to trial discontinuation was 4.0 months in
the two sets (range 0–44 and 0–49, respectively). Most
patients were withdrawn from the study due to disease
progression (Center 1 set: 198, 65 %; Center 2 set: 136,
60 %) or to toxicity (Center 1 set: 32, 11 %; Center 2 set:
37, 16 %). Overall survival at 3 months in the Center 1
and 2 sets were 88 % (95 % CI, 83.5–91.0) and 91 %
(95 % CI, 86.7–94.2), respectively. Life expectancy was
included as an eligibility criterion in 13 trials (73
patients, 24 %) in the Center 1 set and 19 trials (82
patients, 36 %) in the Center 2 set. The presence of life
expectancy among the inclusion criteria did not improve
the 3-month OS in either the Center 1 (hazards ratio
[HR] 0.6, 95 % CI, 0.2–1.2, P = .23) or the Center 2 (HR
0.7, 95 % CI, 0.3–2.0, P = .55) set (Fig. 1).
Factors associated with 3-month early deaths
Results from univariate and multivariate analyses are pre-
sented in Table 3 and Additional file 1: Table S1 (online-
only supplementary material). Factors associated with the
3-month mortality in multivariate analysis in the Center 1
set, after adjustment on age, sex and tumor localization,
included an ECOG performance status of 2 (OR 13.3,
95 % CI, 4.1–43.4), hyperleukocytosis (OR 5.5, 95 % CI,
1.9–16.3) and anemia (OR 2.8, 95 % CI, 1.1–7.1). Based
on these three factors, we calculated a risk (PREDIT
Table 2 Clinical and biological characteristics at baseline for Center 1 and Center 2 sets (Continued)
Normal 236 (78) 111 (50)
NA 32 (11) 28 (12)
LDH level -a
< Normal 133 (44) 137 (60)
Normal 55 (18) 51 (23)
NA 111 (37) 34 (15)
Abbreviations: BMI body mass index, ECOG Eastern Cooperative Oncology Group, IQR interquartile range, LDH lactate dehydrogenase, NA not available
aDue to a non-applicable rate of 10 % or more, BMI, Albumin level and LDH level variables cannot be tested by the chi test
Fig. 1 Overall survival in the two sets. a Overall survival in the Center 1 set (blue) and Center 2 set (red). b Survival depending on the presence
(dotted lines) or absence (full lines) of ‘life expectancy’ criterion for each patient included regarding the respective trial’s protocol, in the Center
1set (blue) and Center 2 set (red)
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model) for patients included in a phase II trial with the
following equation:
Model = 0.4177 x (Age = [50–65[) + 0.5950 x (Age = ≥
65) + 0.7703 x (Sex =Male) - 0.8658 x (Cancer
localization = Breast) - 1.3116 x (Cancer localization
= Urogenital) - 13.3383 x (Cancer localization = Other)
- 1.7239 x (Cancer localization = Gastrointestinal) +
2.5882 x (ECOG = 2) - 0.8887 x (Leukocyte level =
Below the norm) + 1.7050 x (Leukocyte level = Above
the norm) + 1.0323x (Hemoglobin level = Below the
norm)
Risk calculation revealed a good predictive value for
both 3-month and 6-month mortality rates, with AUC
values ranging from 0.7 to 0.9 in both sets. More con-
cretely, in the overall population, patients with 0, 1, 2 and
3 risk factors had a rate of a 3-month early-death of 2 %
(7/292), 14 % (24/175), 38 % (20/53) and 60 % (6/10) and
a rate of 6-month early-death of 7 % (19/292), 28 % (49/
175), 47 % (25/53) and 70 % (7/10), respectively.
Discussion
Phase II trials are crucial screening tools to assess whether
an anti-cancer drug has sufficient activity to warrant further
investigation in large, costly phase III trials. In this respect,
patients should be selected for such trials in a manner that
maximizes the potential to assess the clinical activity of the
investigational drug. Patients in poor conditions and with a
limited life expectancy are not likely to derive significant
benefit from the investigational therapy and inclusion of
such patients may preclude valid conclusions about the
clinical activity of the drug. Therefore, appropriate assess-
ment of life expectancy is crucial to avoid inclusion of pa-
tients who are at higher risk of early death and who have
low probability of clinical benefit. Our prognostic factors,
ECOG performance status of 2, hyperleukocytosis and
anemia, validated in two independent sets, could provide
physicians with an objective tool to help in this assessment.
Performance status is a well-known bad prognostic
factor in oncology, associated with early death and
already described for patients included in phase I trials
[15, 16]. Anemia is very frequent in oncology with a
Table 3 Factors associated with early death at 3 months in the Center 1 set (N = 303)
Univariate analysis Multivariate analysis
Characteristics at baseline Early deaths N (%) OR 95 % CI P OR 95 % CI P
Age 0.01 0.21
< 50 12 (32) 1 1
[50–65] 17 (46) 0.2 [0.1–0.6] 1.8 [0.6–5.7]
≥65 8 (22) 0.6 [0.3–1.4] 0.7 [0.2–2.4]
Sex 0.17 0.1500
Female 11 (30) 1 1
Male 26 (70) 1.7 [0.8–3.5] 2.2 [0.8–6.2]
Performance status <0.001 <0.001
ECOG 0/1 21 (57) 1 1
ECOG 2 16 (43) 21.7 [8.5–54.9] 13.3 [4.1–43.4]
Cancer localization 0.02 0.08
Sarcoma 26 (70) 1 1
Gastrointestinal 4 (11) 0.3 [0.1–0.9] 0.2 [0.0–0.7]
Urological 5 (14) 0.3 [0.1–0.7] 0.3 [0.1–1.2]
Breast 2 (5) 0.3 [0.1–1.2] 0.4 [0.1–1.0]
Other 0 <0.1 [<0.1– > 999] <0.1 [<0.1– > 999]
Hemoglobin level <0.001 0.03
Normal 12 (32) 1 1
< Normal 25 (68) 4.8 [2.3–10.0] 2.8 [1.1–7.1]
Leukocyte level <0.001 0.006
Normal 22 (59) 1 1
< Normal 1 (3) 0.8 [0.1–6.5] 0.4 [0.0–5.4]
> Normal 14 (38) 7.8 [3.4–17.6] 5.5 [1.9–16.3]
Abbreviations: CI confidence interval, ECOG Eastern Cooperative Oncology Group, OR odds ratio
Bold data reflects significant value
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prevalence of 39 % at onset of cancer, and 68 % of pa-
tients present anemia at least once in the subsequent 6
months [17]. It leads to an overall relative increase in
risk of death of 65 % (54–77 %) [18] that can be related
to various factors. A decrease in WHO performance
score and quality of life are well-known consequences
[17] that can limit options for specific cancer treatments.
The worst outcomes associated to anemia can also be
linked to its biological consequences. As an example, a
more aggressive cancer biology is connected to the pro-
motion of hypoxia-inducible factor 1, which is induced
by anemic hypoxia and has been described as a tumor
metastasis enhancer [19]. Initial hyperleukocytosis (often
associated with neutrophilia) is a frequent event in pa-
tients with solid tumors, with an incidence ranging from 4
to 26 % [20], and has been associated with poor outcome
in several solid tumor types [21–28]. Indeed, leukocytosis
is related to tumor burden [27, 29]. Additionally, it can be
a consequence of processes such as infection and/or in-
flammation or corticosteroids treatment [29, 30], which
can themselves be of bad prognostic.
This preliminary study allowed developing a first model
that needs to be validated at the national level. One of the
advantages of a two-step procedure is the possibility to
evaluate the feasibility on the data collection in the med-
ical record. One of the disadvantages is that preliminary
results are not confirmed on a larger population. Besides
the limited power, the main limitation of our study lies in
its retrospective nature. Prospectively defining a model for
patients that would be included in a phase II trial would
be very complex, and, as a consequence, only patients
who passed screening and received at least one dose of
the investigational agent were included in the study (what-
ever the set). One of the strengths of our study is that the
sets originated from two different cancer centers. We
identified the same three prognostic factors in the Center
2 set despite differences in the characteristics of the two
populations. This demonstrates a strong relevance of these
factors to predict early death regardless of the heterogen-
eity of patients, primary tumor sites, treatments and man-
agement strategies. Further work will aim at validating the
model in an independent and wider cohort of patients
such as a national cancer registry.
Conclusions
Risk modeling based on simple clinical parameters in-
cluding hemoglobin level, leukocyte count and ECOG
performance status indicated that patients with two or
more prognostic factors had a significant risk of early
death. Our results clearly suggest that these patients
should be considered carefully for inclusion in a phase II
clinical trial. Our model may represent a helpful tool in
the process of patient selection for phase II trial entry.
Additional file
Additional file 1: Table S1. Univariate analysis of factors non-associated
with 3-month mortality in the multivariate model for the Centre 1 set.
(DOCX 25 kb)
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